UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Apple Turns 50: From Garage Startup to AI Crossroads 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
EMERYVILLE, Calif., July 10, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather. The compensation committee of the company’s board of directors granted Mr. Merriweather a stock option to purchase 112,500 shares of the company’s common stock, at a per share exercise price of $16.98, the closing trading price on July 10, 2017, and restricted stock units to acquire 18,750 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson’s disease, multiple sclerosis, epilepsy, and Alzheimer’s disease. Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response. The company’s most advanced product candidate, ADS-5102, is a high-dose amantadine, taken once-daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease and for the treatment of walking impairment in people with multiple sclerosis. A New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease is under review by the FDA with a PDUFA date of August 24, 2017. Adamas is exploring other indications for further development of ADS-5102. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’ licensed assets, are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
